S. Yan

Essential drugs for cancer therapy: a World Health Organization consultation.

K. Sikora, I. Magrath, H. Pinedo, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer

P. Lønning, A. Buzdar, M. Lichinitser, 2002, Breast Cancer Research and Treatment.

Neferine induces apoptosis by modulating the ROS-mediated JNK pathway in esophageal squamous cell carcinoma

Yuehan Zhang, K. An, Gaifang Liu, 2020, Oncology reports.

Detachment-induced upregulation of XIAP and cIAP2 delays anoikis of intestinal epithelial cells

S. Shirasawa, T. Sasazuki, R. Korneluk, 2006, Oncogene.

Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Controversial Area

Qian-Shu Wang, X. Jia, S. Yan, 2022, Frontiers in Oncology.

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.

E. Jonasch, C. Logothetis, H. Tran, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma].

W. Q. Chen, G. Liu, S. Cai, 2018, Zhonghua zhong liu za zhi [Chinese journal of oncology].

A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC).

E. Jonasch, H. Tran, A. Zurita, 2009, Journal of Clinical Oncology.

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.

E. Jonasch, C. Logothetis, H. Tran, 2012 .